U.S. markets closed

Eisai Co., Ltd. (ESALF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
101.000.00 (0.00%)
At close: 10:56AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close101.00
Open101.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range101.00 - 101.00
52 Week Range67.00 - 108.50
Volume100
Avg. Volume134
Market Cap29.489B
Beta (5Y Monthly)0.50
PE Ratio (TTM)76.17
EPS (TTM)1.33
Earnings DateN/A
Forward Dividend & Yield1.47 (1.46%)
Ex-Dividend DateSep 29, 2021
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate
    Zacks

    Bristol-Myers (BMY) Partners Eisai for Antibody Drug Conjugate

    Bristol-Myers (BMY) teams up with Eisai to co develop MORAb-202, an antibody drug conjugate (ADC).

  • Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product
    Benzinga

    Codexis Raises 2021 Revenue Outlook After New Order For Its Enzyme Product

    View more earnings on CDXSSee more from BenzingaClick here for options trades from BenzingaBioNTech Starts Dosing In Mid-Stage Melanoma Vaccine TrialBristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over B For Rights© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights
    Benzinga

    Bristol Myers Inks Licensing Pact For Eisai's Folate Receptor ADC Drug, Lays Out Over $3B For Rights

    Eisai Co Ltd (OTC: ESALY) and Bristol-Myers Squibb Co (NYSE: BMY) have entered into an exclusive global strategic collaboration agreement for the co-development and co-commercialization of MORAb-202, an antibody-drug conjugate (ADC). Bristol Myers will pay $650 million, including $200 million to Eisai's R&D efforts, for shared global rights to MORAb-202, the Japanese company's first ADC, which is a combination between an in-house folate receptor antibody and chemotherapy eribulin, marketed as Ha